{
    "organizations": [],
    "uuid": "efc92c70cb47783439d7b31b272085daf6d2b195",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ultragenyx-kyowa-kirin-say-crysvit/brief-ultragenyx-kyowa-kirin-say-crysvita-met-main-goal-of-phase-3-study-idUSFWN1SO0P6",
    "ord_in_thread": 0,
    "title": "BRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE TOPLINE PHASE 3 STUDY RESULTS DEMONSTRATING SUPERIORITY OF CRYSVITA® (BUROSUMAB) TREATMENT TO ORAL PHOSPHATE AND ACTIVE VITAMIN D IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH)\n* ULTRAGENYX PHARMACEUTICAL INC - PHASE 3 STUDY OF CRYSVITA® (BUROSUMAB) MET ITS PRIMARY ENDPOINT\n* ULTRAGENYX PHARMACEUTICAL - PHASE 3 STUDY OF CRYSVITA SHOWED IMPROVEMENT IN IMPORTANT METABOLIC AND FUNCTIONAL MEASURES WITH CRYSVITA TREATMENT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T20:39:00.000+03:00",
    "crawled": "2018-05-18T19:46:23.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "ultragenyx",
        "kyowa",
        "kirin",
        "announce",
        "topline",
        "phase",
        "study",
        "result",
        "demonstrating",
        "superiority",
        "burosumab",
        "treatment",
        "oral",
        "phosphate",
        "active",
        "vitamin",
        "child",
        "hypophosphatemia",
        "xlh",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "phase",
        "study",
        "burosumab",
        "met",
        "primary",
        "endpoint",
        "ultragenyx",
        "pharmaceutical",
        "phase",
        "study",
        "crysvita",
        "showed",
        "improvement",
        "important",
        "metabolic",
        "functional",
        "measure",
        "crysvita",
        "treatment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}